Atezolizumab Extends DFS after NSCLC Relapse Available to Purchase

In the phase III IMpower-010 trial, patients with non–small cell lung cancer whose disease returned after surgery and adjuvant chemotherapy received a year of adjuvant therapy with the immune checkpoint inhibitor atezolizumab. Use of this drug was associated with a 34% reduction in the risk of disease progression compared with best supportive care among patients whose tumors expressed PD-L1. The benefit was even greater in patients with PD-L1 expression of at least 50%.